- Home
- PMVP vs ALRN Comparison
PMVP vs ALRN Comparison
Compare PMVP & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ALRN
- Stock Information
- Founded
- PMVP 2013
- ALRN 2001
- Country
- PMVP United States
- ALRN United States
- Employees
- PMVP N/A
- ALRN N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- ALRN Health Care
- Exchange
- PMVP Nasdaq
- ALRN Nasdaq
- Market Cap
- PMVP 85.5M
- ALRN 76.9M
- IPO Year
- PMVP 2020
- ALRN 2017
- Fundamental
- Price
- PMVP $1.51
- ALRN $2.00
- Analyst Decision
- PMVP Strong Buy
- ALRN Strong Buy
- Analyst Count
- PMVP 4
- ALRN 1
- Target Price
- PMVP $5.75
- ALRN $19.00
- AVG Volume (30 Days)
- PMVP 196.4K
- ALRN 92.8K
- Earning Date
- PMVP 11-07-2024
- ALRN 11-14-2024
- Dividend Yield
- PMVP N/A
- ALRN N/A
- EPS Growth
- PMVP N/A
- ALRN N/A
- EPS
- PMVP N/A
- ALRN N/A
- Revenue
- PMVP N/A
- ALRN N/A
- Revenue This Year
- PMVP N/A
- ALRN N/A
- Revenue Next Year
- PMVP N/A
- ALRN N/A
- P/E Ratio
- PMVP N/A
- ALRN N/A
- Revenue Growth
- PMVP N/A
- ALRN N/A
- 52 Week Low
- PMVP $1.40
- ALRN $1.61
- 52 Week High
- PMVP $3.47
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- PMVP 38.59
- ALRN 36.91
- Support Level
- PMVP $1.55
- ALRN $1.86
- Resistance Level
- PMVP $1.61
- ALRN $2.38
- Average True Range (ATR)
- PMVP 0.07
- ALRN 0.30
- MACD
- PMVP -0.01
- ALRN -0.00
- Stochastic Oscillator
- PMVP 18.18
- ALRN 23.42
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.